Topical tacrolimus neither prevents nor abolishes ultraviolet-induced erythema

Journal of the American Academy of Dermatology

Volumn 55, Issue 5, 2006, Pages 882-885

  Gambichler, Thilo ^a   Tomi, Nordwig S ^a   Moussa, Georg ^a   Huyn, Julia ^a   Dickel, Heinrich ^a   Altmeyer, Peter ^a   Kreuter, Alexander ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADULT; ARTICLE; COLORIMETRY; CONTROLLED STUDY; ERYTHEMA; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; SCORING SYSTEM; SKIN INFLAMMATION; TREATMENT FAILURE; TREATMENT OUTCOME; ULTRAVIOLET RADIATION;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; TACROLIMUS; TREATMENT FAILURE; ULTRAVIOLET RAYS;

EID: 33749677318     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.01.039     Document Type: Article

References (17)

1. Soter N.A. Acute effects of ultraviolet radiation on the skin. Semin Dermatol 9 (1990) 11-15
2. Hruza L.L., and Pentland A.P. Mechanisms of UV-induced inflammation. J Invest Dermatol 100 (1993) 35-44
3. Kienzler J.L., Magnette J., Queille-Roussel C., Sanchez-Ponton A., and Ortonne J.P. Diclophenac-Na gel is effective in reducing the pain and inflammation associated with exposure to ultraviolet light-results of two clinical studies. Skin Pharmacol Physiol 18 (2005) 144-152
4. Jocher A., Kessler S., Hornstein S., Schulte-Mönting J., and Schempp C.M. The UV erythema test as a model to investigate the anti-inflammatory potency of topical preparations-reevaluation and optimization of the method. Skin Pharmacol Physiol 18 (2005) 234-240
5. Assmann T., Homey B., and Ruzicka T. Topical tacrolimus for the treatment of inflammatory skin disorders. Expert Opin Pharmacother 2 (2001) 1167-1175
6. Ogawa Y., Adachi A., and Tomita Y. The successful use of topical tacrolimus treatment for a chronic actinic dermatitis patient with complications of idiopathic leukopenia. J Dermatol 30 (2003) 805-809
7. Fitzpatrick T.B. The validity and practicality of sun-reactive skin types I and IV. Arch Dermatol 124 (1988) 869-887
8. Sayre R.M. Solar simulators: used in drug and cosmetic testing. In: Matthes R., and Sliney D. (Eds). Measurements of optical radiation hazards (1998), International Commission on Non-Ionizing Radiation Protection, Munich 685-700
9. Fullerton A., Fischer T., Lahit A., Wilhelm K.P., Takiwaki H., and Serup J. Guidelines for measurement of skin color and erythema: a report from the standardization group of the European Society of Contact Dermatitis. Contact Dermatitis 35 (1996) 1-10
10. Hoffmann K., Kaspar K., Gambichler T., and Altmeyer P. Change in ultraviolet (UV) transmission following the application of vaseline to non-irradiated and UVB-exposed split skin. Br J Dermatol 143 (2000) 532-538
11. Lebwohl M., Martinez J., Weber P., and DeLuca R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol 32 (1995) 469-471
12. Rhodes L.E., Belgi G., Parslew R., McLoughlin L., Clough G.F., and Friedmann P.S. Ultraviolet-B-induced erythema is mediated by nitric oxide and prostaglandin E2 in combination. J Invest Dermatol 117 (2001) 880-885
13. Ring J., Barker J., Behrendt H., Braathen L., Darsow U., Dubertret L., et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors. J Eur Acad Dermatol Venereol 19 (2005) 663-671
14. Lan C.C., Yu H.S., Wu C.S., Kuo H.Y., Chai C.Y., and Chen G.S. FK506 inhibits tumor necrosis factor-α secretion in human keratinocytes via regulation of nuclear factor-κB. Br J Dermatol 153 (2005) 725-732
15. Terui T., and Tagami H. Mediators of inflammation involved in UVB erythema. J Dermatol Sci 23 Suppl (2000) 1-5
16. Brink N., Szamel M., Young A.R., Wittern K.P., and Bergemann J. Comparative quantification of IL-1beta, IL-10, IL-10r, TNFalpha and IL-7 mRNA levels in UV-irradiated human skin in vivo. Inflamm Res 49 (2000) 290-296
17. Billich A., Aschauer H., Aszodi A., and Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 269 (2004) 29-35